COMMUNIQUÉS West-GlobeNewswire

Sapience Therapeutics to Present at Biotech Showcase 2019
11/12/2018
HARRISON, N.Y., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications [...]
Cellectar Granted Japanese Patent for CLR 131
11/12/2018
Patent covers composition of matter and use in solid and liquid tumor cancer indications FLORHAM PARK, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage [...]
Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
11/12/2018
- Gray Recognized for Scientific and Financial Acumen as Board Leader - CAMBRIDGE, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare [...]
Medifirst Solutions to Present at the American Pain Association Conferences Focusing on Medical CBD and the Opioid Epidemic
11/12/2018
Freehold, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared [...]
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
11/12/2018
MYK-491 Demonstrated Increase in Contractility Consistent with Data from Preclinical and Healthy Volunteer Studies Multiple-Ascending Dose Phase 2a Clinical Trial in DCM and Systolic Heart Failure Patients Underway [...]
Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting
11/12/2018
EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]
Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer
11/12/2018
HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/ [...]
Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)
11/12/2018
TORONTO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has formed a 100% owned subsidiary in Australia, named Arch Clinical Pty [...]
Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
11/12/2018
Interim analysis expected as early as Q2 2020 Newark, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael), a leader in the growing field of cancer metabolism-based therapeutics, today announced [...]
NexImmune Granted Key US Patent for Core E+E Technology
11/12/2018
GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office has issued a new [...]
ImmuCell Announces USDA Approval of Dual-Force™ First Defense®
11/12/2018
PORTLAND, Maine, Dec. 11, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
Shockwave Announces collaboration With Abiomed on Physician Training
11/12/2018
Abiomed Invests $15 Million in Shockwave SANTA CLARA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Shockwave Medical, a pioneer in the development and commercialization of intravascular lithotripsy to treat complex [...]
Operation Hat Trick Donates $10,000 to SoldierStrong
11/12/2018
Nonprofit Organizations Share Purpose of Supporting Injured Veterans STAMFORD, Conn. and HAMPTON, N.H., Dec. 11, 2018 (GLOBE NEWSWIRE) -- SoldierStrong, a nonprofit organization dedicated to providing advanced medical [...]
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
11/12/2018
Funding to Help Further Clinical Development of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a [...]
HealthLynked to Attend the 2019 HIMSS Global Conference & Exhibition
11/12/2018
NAPLES, Fla., Dec. 11, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK) today announced that the Company will be attending the HIMSS Global Conference & Exhibition ( Healthcare Information and Management [...]
eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
11/12/2018
SAN DIEGO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it has dosed [...]
Comfort Launch by Vergence Naturals Exceeds Expectations
11/12/2018
VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update on the recent soft-launch of its [...]
CLS Holdings USA, Inc Announces Receipt for Final Prospectus From Ontario Securities Commission and Conditional Approval to List on the Canadian Securities Exchange
11/12/2018
LAS VEGAS, Dec. 11, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “ CLS ,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada [...]
Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
11/12/2018
Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by improvement on the [...]

Pages